Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Strax on an automatic redemption procedure
Mandate

Vinge advised Strax on an automatic redemption procedure

January 30, 2019 Capital Markets and Public M&A

Vinge has advised Strax AB in connection with an automatic redemption procedure according to which each outstanding share in Strax has been split into two shares, of which one share (called redemption share) has been redeemed for a proceed of SEK 1.10.

In aggregate, 120,592,332 shares were redeemed at an amount corresponding to approximately SEK 133 million. The redemption procedure was approved by the extraordinary general meeting on 28 December 2018 and the proceeds in the redemption procedure was paid on 30 January 2019.

Vinge’s team consisted mainly of Jesper Schönbeck, Rikard Lindahl, Malte Hedlund, Anna-Karin Alin and Julia Hirschberg. Maria Schultzberg and Henrik Wastenson advised on tax issues.
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026